Biogen Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIIB Nasdaq 2836 www.biogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biogen Inc.

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease - Sep 16th, 2026 12:00 am
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? - Sep 15th, 2026 1:47 pm
Hummingbird Bioscience Appoints Dr. James Garner as President - Sep 15th, 2026 3:00 am
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience - Sep 14th, 2026 10:02 pm
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Sep 12th, 2026 3:01 pm
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit - Sep 8th, 2026 8:30 am
Lilly Builds Neuroscience into a New Long-Term Growth Driver - Sep 8th, 2026 6:27 am
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. - Sep 4th, 2026 10:13 am
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Sep 4th, 2026 9:30 am
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma? - Sep 3rd, 2026 10:38 pm
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Sep 3rd, 2026 5:30 pm
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients - Sep 3rd, 2026 5:06 am
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Sep 2nd, 2026 10:00 pm
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Sep 2nd, 2026 9:25 pm
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? - Sep 2nd, 2026 9:30 am
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet - Sep 2nd, 2026 1:48 am
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Sep 1st, 2026 5:30 am